MCID: NSP003
MIFTS: 32

Nasopharyngeal Disease

Categories: Respiratory diseases

Aliases & Classifications for Nasopharyngeal Disease

MalaCards integrated aliases for Nasopharyngeal Disease:

Name: Nasopharyngeal Disease 12 15
Nasopharyngeal Diseases 55 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9561
MeSH 44 D009302
NCIt 50 C35723
SNOMED-CT 68 123952009
UMLS 73 C0027438

Summaries for Nasopharyngeal Disease

MalaCards based summary : Nasopharyngeal Disease, also known as nasopharyngeal diseases, is related to nasopharyngitis and stromal keratitis. An important gene associated with Nasopharyngeal Disease is PSMB9 (Proteasome Subunit Beta 9), and among its related pathways/superpathways are IL-17 Family Signaling Pathways and Cytokine production by Th17 cells in CF (Mouse model). The drugs Erythromycin and Analgesics have been mentioned in the context of this disorder. Affiliated tissues include lung, nk cells and bone.

Related Diseases for Nasopharyngeal Disease

Diseases related to Nasopharyngeal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 nasopharyngitis 24.8 ARL2BP DHRS3 DPP4 IL17A IL17F IL17RA
2 stromal keratitis 10.1 IL17A IL17RA
3 familial candidiasis 10.0 IL17F IL17RA
4 opportunistic mycosis 10.0 IL17A IL17RA
5 mastitis 9.8 IL17A LTF
6 chronic mucocutaneous candidiasis 9.7 IL17A IL17F IL17RA
7 candidiasis 9.7 IL17A IL17F IL17RA
8 psoriatic arthritis 9.6 IL17A IL17RA IL36RN
9 acute generalized exanthematous pustulosis 9.6 IL17A IL17F IL36RN

Graphical network of the top 20 diseases related to Nasopharyngeal Disease:



Diseases related to Nasopharyngeal Disease

Symptoms & Phenotypes for Nasopharyngeal Disease

Drugs & Therapeutics for Nasopharyngeal Disease

Drugs for Nasopharyngeal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 277)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
2 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Gastrointestinal Agents Phase 4,Phase 2,Phase 3
4 Cyclooxygenase 2 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
5 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
6 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Erythromycin Estolate Phase 4
10 Erythromycin Ethylsuccinate Phase 4
11 Erythromycin stearate Phase 4
12 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
13 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 3,Not Applicable 154361-50-9 60953
17
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
18
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
19
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
20
Hydroxyurea Approved Phase 3,Phase 1 127-07-1 3657
21
Celecoxib Approved, Investigational Phase 3,Phase 2,Phase 1 169590-42-5 2662
22
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3,Phase 3 128-13-2 31401
23
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
24
Cetuximab Approved Phase 3,Phase 1,Phase 2 205923-56-4 56842117 2333
25
Nedaplatin Approved, Investigational Phase 3,Phase 2,Phase 1 95734-82-0
26
Sulindac Approved, Investigational Phase 3,Phase 2 38194-50-2 5352 1548887
27
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
28
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
29
Budesonide Approved Phase 3,Not Applicable 51333-22-3 63006 5281004
30
Amifostine Approved, Investigational Phase 3,Phase 2 20537-88-6 2141
31
Epirubicin Approved Phase 3 56420-45-2 41867
32
Fluticasone Approved, Experimental, Investigational Phase 3 90566-53-3 62924
33
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
34
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
35
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
36
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
37
Serine Approved, Nutraceutical Phase 3 56-45-1 5951
38
Ornithine Approved, Nutraceutical Phase 3,Phase 2 70-26-8, 3184-13-2 6262
39 Endostatins Phase 3,Phase 2 71581480
40 Alkylating Agents Phase 3,Phase 2,Phase 1
41 glucocorticoids Phase 3,Phase 2,Not Applicable
42
protease inhibitors Phase 3,Phase 2,Early Phase 1
43 Cholagogues and Choleretics Phase 2, Phase 3,Phase 3
44 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
45 HIV Protease Inhibitors Phase 3,Phase 2,Early Phase 1
46 Hormone Antagonists Phase 3,Phase 2,Not Applicable
47 Dermatologic Agents Phase 3,Phase 2
48 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
49 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
50 Hormones Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 387)
# Name Status NCT ID Phase Drugs
1 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
2 Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma Unknown status NCT02293356 Phase 4 Nimotuzumab Injection
3 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
4 Stereotactic Body Radiotherapy for Head and Neck Tumors Unknown status NCT01344356 Phase 4
5 A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients Recruiting NCT02948699 Phase 4
6 A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED) Terminated NCT00140894 Phase 4 MK0966; rofecoxib / Duration of Treatment: 24 weeks;Comparator: placebo / Duration of Treatment: 24 weeks
7 A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma Unknown status NCT02444949 Phase 3 endostar;cisplatin
8 The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma Unknown status NCT02537925 Phase 3 Celecoxib;Nedaplatin
9 Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma Unknown status NCT02301208 Phase 3 Nedaplatin;Cisplatin
10 Phase Ⅲ Study of Neoadjuvant TPF Chemotherapy Followed by Radiotherapy and Concurrent Nimotuzumab or Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC). Unknown status NCT02012062 Phase 3 TPF neoadjuvant chemotherapy;Concurrent chemotherapy with cisplatin during radiotherapy;Concurrent nimotuzumab during radiotherapy
11 Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT01915134 Phase 3 Recombinant Human Endostatin plus gemcitabine and cisplatin;Gemcitabine and cisplatin
12 Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC Unknown status NCT01854203 Phase 2, Phase 3 Inductive chemotherapy + concurrent cisplatin and IMRT;Inductive chemotherapy + IMRT
13 The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT Unknown status NCT01817023 Phase 3 Cisplatin
14 Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer Unknown status NCT01689558 Phase 2, Phase 3 Recombine Endostatin
15 Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma Unknown status NCT01536223 Phase 3 PF (cisplatin and 5-fluorouracil) group;TPF (docetaxel plus cisplatin and 5-fluorouracil) group
16 Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma Unknown status NCT01528618 Phase 3 gemcitabine and cisplatin;5-Fluorouracil and cisplatin
17 A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01479504 Phase 3 nedaplatin and docetaxel;cisplatin and docetaxel;nedaplatin and docetaxel;cisplatin and docetaxel
18 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
19 Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01245959 Phase 3 Docetaxel, cisplatin and fluorouracil
20 A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00705627 Phase 3 neoadjuvant chemotherapy plus concurrent chemoradiotherapy
21 Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00677118 Phase 3 Cisplatin,fluorouracil;Cisplatin
22 PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCIN Unknown status NCT00180973 Phase 3 Hydroxyurea
23 Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients Unknown status NCT00134758 Phase 2, Phase 3 Ursodeoxycholic acid;Placebo
24 Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Exten Completed NCT01622569 Phase 3 rescue med
25 Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma Completed NCT01540136 Phase 3 Nedaplatin;Cisplatin
26 Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis Completed NCT01197612 Phase 3 pulmicort
27 Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis Completed NCT00808743 Phase 2, Phase 3 Celecoxib;Ursodeoxycholic acid;Placebo
28 Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma Completed NCT00778908 Phase 2, Phase 3 Concomitant cisplatin chemotherapy
29 Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA Completed NCT00535795 Phase 3
30 Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA Completed NCT00510692 Phase 2, Phase 3 Eicosapentanoic Acid (EPA);Placebo
31 Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer Completed NCT00274937 Phase 3 amifostine trihydrate;fluorouracil;cisplatin
32 A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma Completed NCT00201396 Phase 3 Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin
33 Adjuvant PD-1 Antibody in Locoregionally Advanced Nasopharyngeal Carcinoma Recruiting NCT03427827 Phase 3 PD-1 antibody
34 TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC Recruiting NCT03574324 Phase 3 TPF+CCRT;CCRT+PF
35 Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage Recruiting NCT03403829 Phase 3 Gemcitabine
36 Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis Recruiting NCT03401229 Phase 3
37 Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients Recruiting NCT03387774 Phase 3 Cisplatin;Ulinastatin
38 Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC Recruiting NCT03366415 Phase 3 gemcitabine and cisplatin (Induction and adjuvant chemotherapy);gemcitabine and cisplatin (Induction chemotherapy)
39 Mometasone vs Budesonide in CRS With Polyposis Recruiting NCT03323866 Phase 3 Budesonide 0.5 MG/ML;Mometasone nasal spray
40 Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma Recruiting NCT03321539 Phase 3 CCRT+GP;CCRT+PF
41 TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma Recruiting NCT03306121 Phase 3 TPF+CCRT;CCRT+ PF
42 Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma Recruiting NCT03015727 Phase 3 Docetaxel;Cisplatin;Chemotherapy
43 EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) Patients Recruiting NCT03006588 Phase 2, Phase 3
44 Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients Recruiting NCT02973386 Phase 2, Phase 3 IMRT combine with cisplatin concurrent chemotherapy;IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
45 Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Recruiting NCT02958111 Phase 3 Capecitabine
46 Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma Recruiting NCT02944708 Phase 3 Conventional chemotherapy;Maintenance chemotherapy 1;Maintenance chemotherapy 2
47 TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma Recruiting NCT02940925 Phase 3
48 Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era Recruiting NCT02633202 Phase 3 Cisplatin
49 Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma Recruiting NCT02633176 Phase 3 Cetuximab;Cisplatin;Docetaxel;Capecitabine
50 Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma Recruiting NCT02610010 Phase 3 Cisplatin

Search NIH Clinical Center for Nasopharyngeal Disease

Cochrane evidence based reviews: nasopharyngeal diseases

Genetic Tests for Nasopharyngeal Disease

Anatomical Context for Nasopharyngeal Disease

MalaCards organs/tissues related to Nasopharyngeal Disease:

41
Lung, Nk Cells, Bone, Colon, Liver, Brain, Temporal Lobe

Publications for Nasopharyngeal Disease

Articles related to Nasopharyngeal Disease:

# Title Authors Year
1
Expression of GRIN2A in benign and malignant nasopharyngeal diseases and its clinical significance. ( 26681223 )
2015
2
Nasopharyngeal disease in cats: 1. Diagnostic investigation. ( 22511473 )
2012
3
Nasopharyngeal disease in cats: 2. Specific conditions and their management. ( 22511474 )
2012
4
Surgical treatment of benign nasopharyngeal disease in the adult. ( 14943338 )
1952

Variations for Nasopharyngeal Disease

Expression for Nasopharyngeal Disease

Search GEO for disease gene expression data for Nasopharyngeal Disease.

Pathways for Nasopharyngeal Disease

Pathways related to Nasopharyngeal Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.46 IL17A IL17F IL17RA
2
Show member pathways
10.77 IL17A IL17F IL17RA

GO Terms for Nasopharyngeal Disease

Cellular components related to Nasopharyngeal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.17 DPP4 IL17A IL17F IL17RA IL36RN LTF

Biological processes related to Nasopharyngeal Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.8 DPP4 LTF PCSK9 PSMB9
2 regulation of signaling receptor activity GO:0010469 9.71 IL17A IL17F IL36RN PCSK9
3 cytokine-mediated signaling pathway GO:0019221 9.67 IL17A IL17F IL36RN LRRC4
4 bone morphogenesis GO:0060349 9.48 DHRS3 LTF
5 defense response to fungus GO:0050832 9.46 IL17A IL17RA
6 positive regulation of interleukin-6 secretion GO:2000778 9.43 IL17A IL17F
7 positive regulation of interleukin-23 production GO:0032747 9.32 IL17A IL17RA
8 antifungal humoral response GO:0019732 9.26 IL36RN LTF
9 fibroblast activation GO:0072537 9.16 IL17A IL17RA
10 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.13 IL17A IL17F IL17RA
11 interleukin-17-mediated signaling pathway GO:0097400 8.8 IL17A IL17F IL17RA

Molecular functions related to Nasopharyngeal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.43 DPP4 LTF PCSK9
2 cytokine activity GO:0005125 9.33 IL17A IL17F IL36RN
3 peptidase activity GO:0008233 9.26 DPP4 LTF PCSK9 PSMB9
4 serine-type peptidase activity GO:0008236 8.8 DPP4 LTF PCSK9
5 protein binding GO:0005515 10.06 ARL2BP DPP4 IL17A IL17F IL17RA IL36RN

Sources for Nasopharyngeal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....